x
Filter:
Filters applied
- ISCT Publications
- mesenchymal stromal cellsRemove mesenchymal stromal cells filter
- 2021 - 2023Remove 2021 - 2023 filter
Author
- Ashford, Paul1
- Brizzi, Maria Felice1
- Choo, Andre Boon Hwa1
- Ciccocioppo, Rachele1
- Davidson, Sean M1
- Dominici, Massimo1
- Galipeau, Jacques1
- Giebel, Bernd1
- Gimona, Mario1
- Grillari, Johannes1
- Hermann, Dirk M1
- Hill, Andrew F1
- Krampera, Mauro1
- Lai, Charles P1
- Lai, Ruenn Chai1
- Lim, Rebecca1
- Lim, Sai Kiang1
- Martin, Ivan1
- Monguió-Tortajada, Marta1
- Moniz, Karen1
- Muraca, Maurizio1
- Nolta, Jan1
- Ochiya, Takahiro1
- Ortiz, Luis A1
- Phinney, Donald G1
ISCT Publications
2 Results
- Short ReportOpen Access
Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells
CytotherapyVol. 23Issue 12p1060–1063Published online: June 9, 2021- Sowmya Viswanathan
- Rachele Ciccocioppo
- Jacques Galipeau
- Mauro Krampera
- Katarina Le Blanc
- Ivan Martin
- and others
Cited in Scopus: 10The Cellular Therapy Coding and Labeling Advisory Group of the International Council for Commonality in Blood Banking Automation and the International Society for Cell & Gene Therapy mesenchymal stromal cell (MSC) committee are providing specific recommendations on abbreviating tissue sources of culture-adapted MSCs. These recommendations include using abbreviations based on the ISBT 128 terminology model that specifies standard class names to distinguish cell types and tissue sources for culture-adapted MSCs. - Featured Article from the ISCT Exosomes Scientific Committee
Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles
CytotherapyVol. 23Issue 5p373–380Published online: April 9, 2021- Mario Gimona
- Maria Felice Brizzi
- Andre Boon Hwa Choo
- Massimo Dominici
- Sean M. Davidson
- Johannes Grillari
- and others
Cited in Scopus: 80Mesenchymal stromal/stem cells (MSCs) have been widely tested against many diseases, with more than 1000 registered clinical trials worldwide. Despite many setbacks, MSCs have been approved for the treatment of graft-versus-host disease and Crohn disease. However, it is increasingly clear that MSCs exert their therapeutic functions in a paracrine manner through the secretion of small extracellular vesicles (sEVs) of 50–200 nm in diameter. Unlike living cells that can persist long-term, sEVs are non-living and non-replicative and have a transient presence in the body.